Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 12/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.44 |
| ▸ | GAA | P10253 | 6/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3134656 | 0.83 | MAPT (0.49) | MEN1KMT2ASMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL3134661 | 0.83 | MAPT (0.49) | MEN1KMT2ASMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL27567617 | 0.83 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL27503707 | 0.83 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL8072839 | 0.81 | MEN1 (0.61) | MEN1KMT2ASMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL503775 | 0.81 | MEN1 (0.75) | MEN1KMT2ASMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL22939653 | 0.79 | MEN1 (0.77) | MEN1KMT2ASMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL16507813 | 0.76 | MEN1 (0.56) | MEN1KMT2ASMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL1178123 | 0.76 | CA12 (0.57) | MEN1KMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL1178120 | 0.76 | CA12 (0.57) | MEN1KMT2ASMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-7449315-B2 | Bifunctional energy-reversible acyl-compositions | CRYOLIFE, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| US-20070167644-A1 | BIFUNCTIONAL ENERGY-REVERSIBLE ACYL-COMPOSITIONS | CRYOLIFE, INC. (US) | 2007-07-19 | — | — | US | disclosed |
| US-20060106204-A1 | Bifunctional energy-reversible acyl-compositions | GILBERT CARL W | 2006-05-18 | — | — | US | disclosed |
| US-20020187993-A1 | Bifunctional energy-reversible acyl-compositions | CRYOLIFE, INC. | 2002-12-12 | — | — | US | disclosed |
| EP-0489836-B1 | LIGHT ACTIVATED ACYL-ENZYMES | UNIV DUKE (US) | 1994-12-21 | — | — | EP | disclosed |
| US-5218137-A | Chemical light amplifiers | DUKE UNIVERSITY (US) | 1993-06-08 | — | — | US | disclosed |
| EP-0489836-A4 | LIGHT ACTIVATED ACYL-ENZYMES | — | 1993-05-26 | — | — | EP | disclosed |
| EP-0489836-A1 | LIGHT ACTIVATED ACYL-ENZYMES. | UNIV DUKE (US) | 1992-06-17 | — | — | EP | disclosed |
| US-5114851-A | Serine- or cysteine-containing protease modified by nucleophilic cinnamic acid; photoisomerization; biological switches; medical diagnosis | DUKE UNIVERSITY (US) | 1992-05-19 | — | — | US | disclosed |
| WO-1991003549-A1 | LIGHT ACTIVATED ACYL-ENZYMES | DUKE UNIVERSITY (US) | 1991-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | MEN1 3638/4885KMT2A 1108/4885SMN1; SMN2 862/4885 |
| US-20020187993-A1 | Bifunctional energy-reversible acyl-compositions | ACACB, ACACA, ACAT1 | MEN1 2183/4885KMT2A 1494/4885SMN1; SMN2 2626/4885 |
| US-20070167644-A1 | BIFUNCTIONAL ENERGY-REVERSIBLE ACYL-COMPOSITIONS | ACACB, ACAT1, ACACA | MEN1 2547/4885KMT2A 1444/4885SMN1; SMN2 2834/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | MEN1 4701/4885KMT2A 2353/4885SMN1; SMN2 1238/4885 |
| US-20060106204-A1 | Bifunctional energy-reversible acyl-compositions | ACACB, ACAT1, ACACA | MEN1 2547/4885KMT2A 1444/4885SMN1; SMN2 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.